Brief: Sciclone Pharmaceuticals Says Approval On Biologics License Application Of Danyelza

SciClone Pharmaceuticals (Holdings)

08/12/2022 10:23

Dec 8 (Reuters) - SciClone Pharmaceuticals  6600.HK :
    * NATIONAL MEDICAL PRODUCTS ADMINISTRATION CHINA APPROVED
BIOLOGICS LICENSE APPLICATION OF DANYELZA
    * LICENSE APPLICATION APPROVAL OF DANYELZA FOR PATIENTS WITH
RELAPSED OR REFRACTORY HIGH-RISK NEUROBLASTOMA

Further company coverage:  6600.HK 
 ((Reuters.Briefs@thomsonreuters.com;))